Biodefence and Vaccine Development
Vaccines remain at the core of biodefence strategies. The accelerated vaccine development seen during COVID-19 has highlighted the importance of preparedness. Companies are now using mRNA and recombinant DNA technologies to create vaccines against potential bioterror pathogens like anthrax, smallpox, and plague.
The biodefence sector is investing in faster clinical trials, modular vaccine platforms, and broader immunization strategies. These advances ensure that governments can respond swiftly to future outbreaks. As research accelerates, the Biodefence Market continues to expand, driven by public-private partnerships and rising global health concerns.
FAQsQ1: What role do vaccines play in biodefence?A1: They provide immunity against potential bioterrorism agents and fast-spreading infectious diseases.
Q2: Which vaccine technologies are being prioritized?A2: mRNA, recombinant DNA, and vector-based vaccine platforms.